Ashley Wood
Psychiatric/Mental Health · Pittsburgh, PANPI 1831718147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 401 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$741
- Alkermes, Inc.$710
- Otsuka America Pharmaceutical, Inc.$544
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$518
- Neurocrine Biosciences, Inc.$446
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,69399%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $1,463 |
| Vanda Pharmaceuticals Inc. | 37 | $741 |
| Alkermes, Inc. | 43 | $710 |
| Otsuka America Pharmaceutical, Inc. | 31 | $544 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $518 |
| Neurocrine Biosciences, Inc. | 34 | $446 |
| Teva Pharmaceuticals USA, Inc. | 16 | $324 |
| Axsome Therapeutics, Inc. | 28 | $310 |
| Lundbeck LLC | 23 | $299 |
| Supernus Pharmaceuticals, Inc. | 23 | $264 |
| Almatica Pharma LLC | 15 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $212 |
| Corium, LLC | 14 | $159 |
| Tris Pharma Inc | 6 | $122 |
| Bausch Health US, LLC | 5 | $89 |
| Johnson & Johnson | 4 | $81 |
| Idorsia Pharmaceuticals US Inc | 3 | $74 |
| Indivior Inc. | 2 | $45 |
| Noven Therapeutics, LLC | 2 | $30 |
| Sage Therapeutics, LLC | 1 | $27 |
| Eisai Inc. | 1 | $25 |
| Seagen Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$114
How this compares
$6,740 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 104 | $146,105 |
| IngrezzaValbenazine Tosylate | 19 | $143,288 |
| LatudaLurasidone Hcl | 22 | $36,671 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $32,739 |
| AuvelityDextromethorphan Hbr/Bupropion | 24 | $25,583 |
| CaplytaLumateperone Tosylate | 13 | $23,258 |
| RexultiBrexpiprazole | 11 | $16,185 |
| TrintellixVortioxetine Hydrobromide | 27 | $13,592 |
| PristiqDesvenlafaxine Succinate | 26 | $10,914 |
| Aripiprazole | 50 | $7,259 |
| BelsomraSuvorexant | 11 | $4,773 |
| Lisdexamfetamine Dimesylate | 23 | $3,966 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $3,570 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 112 | $3,539 |
| Bupropion XlBupropion Hcl | 84 | $3,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,463 | $146,105104 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $446 | $143,28819 claims |
| Alkermes, Inc.Lybalvi | $710 | $32,73921 claims |
| Axsome Therapeutics, Inc.Auvelity | $310 | $25,58324 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $518 | $23,25813 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $544 | $16,18511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $212 | $13,59227 claims |
| Almatica Pharma LLCSertraline Hcl | $243 | $1,48696 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Pittsburgh
- Britney KeplerPittsburgh$158K
- Amanda CieszynskiPittsburgh$8K
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.